Can GLP‑1 drugs help treat addiction?

New evidence points to a possible role for GLP‑1 drugs in substance use care

Researchers and clinicians are increasingly examining whether medications developed for diabetes and weight loss could also reduce harmful substance use. Multiple observational studies and early experimental work suggest users of glucagon‑like peptide‑1 (GLP‑1) receptor agonists show lower rates of some substance use disorders and related harms.

What the studies show

• Large observational cohorts, including research among U.S. veterans, have reported associations between starting GLP‑1 therapy and reduced incidence of alcohol, cannabis and opioid use disorders. Some studies also link GLP‑1 initiation with fewer overdoses among people who use substances.
• Preclinical work in animals and small human studies point to plausible biological mechanisms: GLP‑1 receptors exist in brain regions that regulate reward and motivation, and activating those receptors can blunt drug‑seeking behaviour in laboratory models.

Important caveats

• The bulk of the evidence is observational or preclinical. Associations do not prove causation, and people prescribed GLP‑1s differ in important ways from those who are not. Randomised clinical trials testing GLP‑1 drugs specifically for addiction outcomes are limited or ongoing.
• Safety and side effects remain relevant. While GLP‑1s can reduce appetite and weight, studies presented to medical audiences have also flagged small but noteworthy risks — for example, signals about bone health and gout have emerged — which matter when considering new uses.

What this means for patients and clinicians

• The findings are promising and have prompted calls for controlled trials to test efficacy for alcohol, opioid and stimulant disorders. If benefits are confirmed, GLP‑1s could become an additional tool alongside counselling, existing medications and harm‑reduction services.
• For now, GLP‑1 prescriptions for addiction would be considered off‑label in most settings; clinicians should weigh potential benefits against known risks and ensure close monitoring.

Key takeaways

• Early data are encouraging but not definitive.
• Biological plausibility exists, but high‑quality clinical trials are needed.
• Safety, access and equitable implementation will shape any future role for these drugs in addiction care.